Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and D A7R d...
Gespeichert in:
| Veröffentlicht in: | Drug delivery 2017, Vol.24 (1), p.1045-1055 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1055 |
|---|---|
| container_issue | 1 |
| container_start_page | 1045 |
| container_title | Drug delivery |
| container_volume | 24 |
| creator | Zhang, Yue Zhai, Meifang Chen, Zhijiang Han, Xiaoyang Yu, Fanglin Li, Zhiping Xie, Xiangyang Han, Cuiyan Yu, Lian Yang, Yang Mei, Xingguo |
| description | Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and
D
A7R dual peptides-modified liposomes (abbreviated as T7/
D
A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma.
D
A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/
D
A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy. |
| doi_str_mv | 10.1080/10717544.2017.1344334 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2195232030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cc477df9efd74636afd268fd9770bb42</doaj_id><sourcerecordid>2195232030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-55e0547831763a3b67c2a81f87026b70823631684a92715b0aa4f262ec01744b3</originalsourceid><addsrcrecordid>eNp9kUtv1DAURiMEoqXwE0CRWGfw284GgcqrUiU2sLZu_Eg9SuJgJwPz7_E8WtENK1v2uede-6uq1xhtMFLoHUYSS87YhiAsN5gyRil7Ul1iTnCDmGBPy74wzQG6qF7kvEUIKUz48-qCKKEkYuyyWj-tMDRjtMEHZ-shzDHH0dUmWjeEnUv7Ovraxj8xrV0wYaphsvUuTCaFvITJ1WGcU9y5eoHUu3LSH4nlziWY3boEUzvvgwFzNPVDiCO8rJ55GLJ7dV6vqp9fPv-4_tbcfv96c_3xtjFckKXh3CHOpKJYCgq0E9IQUNiX2YnoJFKECoqFYtASiXmHAJgngjhT_oSxjl5VNyevjbDVcwojpL2OEPTxIKZeQyojDk4bw6S0vnXeSiaoAG-JUN62UqKuY6S43p9c89qNzho3LQmGR9LHN1O4033caUUYahUtgrdnQYq_VpcXvY1rmsr7NcEtJ5QgigrFT5RJMefk_EMHjPQheX2fvD4kr8_Jl7o3_473UHUfdQE-nIAw-ZhG-B3TYPUC-yEmn2AyIWv6_x5_AQ4SvsQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2195232030</pqid></control><display><type>article</type><title>Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Yue ; Zhai, Meifang ; Chen, Zhijiang ; Han, Xiaoyang ; Yu, Fanglin ; Li, Zhiping ; Xie, Xiangyang ; Han, Cuiyan ; Yu, Lian ; Yang, Yang ; Mei, Xingguo</creator><creatorcontrib>Zhang, Yue ; Zhai, Meifang ; Chen, Zhijiang ; Han, Xiaoyang ; Yu, Fanglin ; Li, Zhiping ; Xie, Xiangyang ; Han, Cuiyan ; Yu, Lian ; Yang, Yang ; Mei, Xingguo</creatorcontrib><description>Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and
D
A7R dual peptides-modified liposomes (abbreviated as T7/
D
A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma.
D
A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/
D
A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.</description><identifier>ISSN: 1071-7544</identifier><identifier>EISSN: 1521-0464</identifier><identifier>DOI: 10.1080/10717544.2017.1344334</identifier><identifier>PMID: 28687044</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>A7R peptide ; Angiogenesis ; Biomedical materials ; Blood-brain barrier ; Brain cancer ; Brain Neoplasms ; brain targeted drug delivery ; Cancer therapies ; Cell Line, Tumor ; Chemotherapy ; da7r peptide ; Doxorubicin ; Drug Delivery Systems ; Drug resistance ; Endothelium ; Gene expression ; Glioma ; Humans ; Laboratories ; Ligands ; Lipids ; Liposomes ; Nanoparticles ; Peptides ; Permeability ; Pharmaceutical sciences ; Pharmacy ; Physiology ; T7 peptide ; Toxicology ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A ; Vincristine</subject><ispartof>Drug delivery, 2017, Vol.24 (1), p.1045-1055</ispartof><rights>2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2017</rights><rights>2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2017 The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-55e0547831763a3b67c2a81f87026b70823631684a92715b0aa4f262ec01744b3</citedby><cites>FETCH-LOGICAL-c562t-55e0547831763a3b67c2a81f87026b70823631684a92715b0aa4f262ec01744b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240983/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240983/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,4010,27479,27900,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28687044$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhai, Meifang</creatorcontrib><creatorcontrib>Chen, Zhijiang</creatorcontrib><creatorcontrib>Han, Xiaoyang</creatorcontrib><creatorcontrib>Yu, Fanglin</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><creatorcontrib>Xie, Xiangyang</creatorcontrib><creatorcontrib>Han, Cuiyan</creatorcontrib><creatorcontrib>Yu, Lian</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Mei, Xingguo</creatorcontrib><title>Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma</title><title>Drug delivery</title><addtitle>Drug Deliv</addtitle><description>Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and
D
A7R dual peptides-modified liposomes (abbreviated as T7/
D
A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma.
D
A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/
D
A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.</description><subject>A7R peptide</subject><subject>Angiogenesis</subject><subject>Biomedical materials</subject><subject>Blood-brain barrier</subject><subject>Brain cancer</subject><subject>Brain Neoplasms</subject><subject>brain targeted drug delivery</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>da7r peptide</subject><subject>Doxorubicin</subject><subject>Drug Delivery Systems</subject><subject>Drug resistance</subject><subject>Endothelium</subject><subject>Gene expression</subject><subject>Glioma</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Ligands</subject><subject>Lipids</subject><subject>Liposomes</subject><subject>Nanoparticles</subject><subject>Peptides</subject><subject>Permeability</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacy</subject><subject>Physiology</subject><subject>T7 peptide</subject><subject>Toxicology</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vincristine</subject><issn>1071-7544</issn><issn>1521-0464</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUtv1DAURiMEoqXwE0CRWGfw284GgcqrUiU2sLZu_Eg9SuJgJwPz7_E8WtENK1v2uede-6uq1xhtMFLoHUYSS87YhiAsN5gyRil7Ul1iTnCDmGBPy74wzQG6qF7kvEUIKUz48-qCKKEkYuyyWj-tMDRjtMEHZ-shzDHH0dUmWjeEnUv7Ovraxj8xrV0wYaphsvUuTCaFvITJ1WGcU9y5eoHUu3LSH4nlziWY3boEUzvvgwFzNPVDiCO8rJ55GLJ7dV6vqp9fPv-4_tbcfv96c_3xtjFckKXh3CHOpKJYCgq0E9IQUNiX2YnoJFKECoqFYtASiXmHAJgngjhT_oSxjl5VNyevjbDVcwojpL2OEPTxIKZeQyojDk4bw6S0vnXeSiaoAG-JUN62UqKuY6S43p9c89qNzho3LQmGR9LHN1O4033caUUYahUtgrdnQYq_VpcXvY1rmsr7NcEtJ5QgigrFT5RJMefk_EMHjPQheX2fvD4kr8_Jl7o3_473UHUfdQE-nIAw-ZhG-B3TYPUC-yEmn2AyIWv6_x5_AQ4SvsQ</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Zhang, Yue</creator><creator>Zhai, Meifang</creator><creator>Chen, Zhijiang</creator><creator>Han, Xiaoyang</creator><creator>Yu, Fanglin</creator><creator>Li, Zhiping</creator><creator>Xie, Xiangyang</creator><creator>Han, Cuiyan</creator><creator>Yu, Lian</creator><creator>Yang, Yang</creator><creator>Mei, Xingguo</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2017</creationdate><title>Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma</title><author>Zhang, Yue ; Zhai, Meifang ; Chen, Zhijiang ; Han, Xiaoyang ; Yu, Fanglin ; Li, Zhiping ; Xie, Xiangyang ; Han, Cuiyan ; Yu, Lian ; Yang, Yang ; Mei, Xingguo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-55e0547831763a3b67c2a81f87026b70823631684a92715b0aa4f262ec01744b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>A7R peptide</topic><topic>Angiogenesis</topic><topic>Biomedical materials</topic><topic>Blood-brain barrier</topic><topic>Brain cancer</topic><topic>Brain Neoplasms</topic><topic>brain targeted drug delivery</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>da7r peptide</topic><topic>Doxorubicin</topic><topic>Drug Delivery Systems</topic><topic>Drug resistance</topic><topic>Endothelium</topic><topic>Gene expression</topic><topic>Glioma</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Ligands</topic><topic>Lipids</topic><topic>Liposomes</topic><topic>Nanoparticles</topic><topic>Peptides</topic><topic>Permeability</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacy</topic><topic>Physiology</topic><topic>T7 peptide</topic><topic>Toxicology</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhai, Meifang</creatorcontrib><creatorcontrib>Chen, Zhijiang</creatorcontrib><creatorcontrib>Han, Xiaoyang</creatorcontrib><creatorcontrib>Yu, Fanglin</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><creatorcontrib>Xie, Xiangyang</creatorcontrib><creatorcontrib>Han, Cuiyan</creatorcontrib><creatorcontrib>Yu, Lian</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Mei, Xingguo</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drug delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yue</au><au>Zhai, Meifang</au><au>Chen, Zhijiang</au><au>Han, Xiaoyang</au><au>Yu, Fanglin</au><au>Li, Zhiping</au><au>Xie, Xiangyang</au><au>Han, Cuiyan</au><au>Yu, Lian</au><au>Yang, Yang</au><au>Mei, Xingguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma</atitle><jtitle>Drug delivery</jtitle><addtitle>Drug Deliv</addtitle><date>2017</date><risdate>2017</risdate><volume>24</volume><issue>1</issue><spage>1045</spage><epage>1055</epage><pages>1045-1055</pages><issn>1071-7544</issn><eissn>1521-0464</eissn><abstract>Therapeutic outcome for the treatment of glioma was often limited due to drug resistance and low permeability of drug across the multiple physiological barriers, including the blood-brain barrier (BBB), and the blood-tumor barrier (BTB). In order to overcome these hurdles, we designed T7 and
D
A7R dual peptides-modified liposomes (abbreviated as T7/
D
A7R-LS) to efficiently co-delivery doxorubicin (DOX) and vincristine (VCR) to glioma in this study. T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma.
D
A7R is a d-peptide ligand of vascular endothelial growth factor receptor 2 (VEGFR 2) overexpressed on angiogenesis, presenting excellent glioma-homing property. By combining the dual-targeting delivery effect, the dual-modified liposomes displayed higher glioma localization than that of single ligand-modified liposomes or free drug. After loading with DOX and VCR, T7/
D
A7R-LS showed the most favorable antiglioma effect in vivo. In conclusion, this dual-targeting, co-delivery strategy provides a potential method for improving brain drug delivery and antiglioma treatment efficacy.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>28687044</pmid><doi>10.1080/10717544.2017.1344334</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1071-7544 |
| ispartof | Drug delivery, 2017, Vol.24 (1), p.1045-1055 |
| issn | 1071-7544 1521-0464 |
| language | eng |
| recordid | cdi_proquest_journals_2195232030 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | A7R peptide Angiogenesis Biomedical materials Blood-brain barrier Brain cancer Brain Neoplasms brain targeted drug delivery Cancer therapies Cell Line, Tumor Chemotherapy da7r peptide Doxorubicin Drug Delivery Systems Drug resistance Endothelium Gene expression Glioma Humans Laboratories Ligands Lipids Liposomes Nanoparticles Peptides Permeability Pharmaceutical sciences Pharmacy Physiology T7 peptide Toxicology Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A Vincristine |
| title | Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A33%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual-modified%20liposome%20codelivery%20of%20doxorubicin%20and%20vincristine%20improve%20targeting%20and%20therapeutic%20efficacy%20of%20glioma&rft.jtitle=Drug%20delivery&rft.au=Zhang,%20Yue&rft.date=2017&rft.volume=24&rft.issue=1&rft.spage=1045&rft.epage=1055&rft.pages=1045-1055&rft.issn=1071-7544&rft.eissn=1521-0464&rft_id=info:doi/10.1080/10717544.2017.1344334&rft_dat=%3Cproquest_pubme%3E2195232030%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2195232030&rft_id=info:pmid/28687044&rft_doaj_id=oai_doaj_org_article_cc477df9efd74636afd268fd9770bb42&rfr_iscdi=true |